EGSYS Score for Syncope
Evaluation of Guidelines in SYncope Study score. Identifies cardiac vs non-cardiac cause of syncope to guide investigation and risk stratification.
Score interpretation
→ EGSYS ≥3: Likely cardiac cause of syncope. Admit for cardiac monitoring; echocardiogram; Holter/telemetry; cardiology review. High risk of recurrence and mortality.
→ EGSYS 1–2: Intermediate probability. Extended monitoring; ECG; basic bloods; consider loop recorder if recurrent.
→ EGSYS ≤0: Likely vasovagal or reflex syncope. Education and reassurance. Avoid triggers; increase fluid/salt intake. Discharge with syncope advice; outpatient tilt testing if uncertain.
Interpretation bands for the EGSYS Score. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
- Lidocaine IV (Cardiac Arrhythmia) · Antiarrhythmic
- Protamine Sulphate (Heparin Reversal) · Heparin Reversal / Cardiac Surgery
- Mavacamten · Cardiac myosin inhibitor
- Digoxin · Cardiac Glycoside
- Aprotinin · Antifibrinolytic — Cardiac Surgery
- Protamine Sulphate · Heparin Antidote — Vascular / Cardiac Surgery
- Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
- NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines
Featured in these MRCEM clinical pathways
The EGSYS Score is covered in detail — with RCEM/NICE evidence base, indications and pitfalls — in the following exam-focused pathways on our sister siteReviseMRCEM.
MRCEM Primary / Intermediate / OSCE candidates: each pathway includes exam-style questions, RCEM/NICE citations, and FAQ summaries.
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.